Race, Screening, and the $2 Million Cure

Sickle cell disease was the first illness understood at the molecular level and one of the last to receive a therapy that matched the science. In 1949, Linus Pauling used protein electrophoresis to show that hemoglobin from people with sickle cell anemia carried a different electrical charge than normal hemoglobin. He called it a "molecular disease," the first time anyone had traced a clinical condition to a single abnormal protein. Seventy-four years passed between that paper and the FDA's approval, in December 2023, of two gene therapies capable of eliminating the disease's defining symptom. The delay was not scientific. The science was always ahead. The delay was about who gets sick.

The Disease

Sickle cell disease is caused by a point mutation in the HBB gene, which encodes the beta-globin subunit of hemoglobin. The mutation substitutes valine for glutamic acid at the sixth position of the protein chain. Under low-oxygen conditions, the altered hemoglobin (hemoglobin S) polymerizes into rigid fibers that distort red blood cells into a crescent shape. These sickled cells block small blood vessels, starve tissue of oxygen, and trigger episodes of extreme pain called vaso-occlusive crises.

The condition is autosomal recessive. A person who inherits one copy of the sickle mutation (sickle cell trait) is generally healthy and produces enough normal hemoglobin to prevent sickling under ordinary conditions. A person who inherits two copies (homozygous SS, or sickle cell anemia) has the most severe form. Compound heterozygous states, including hemoglobin SC disease and sickle beta-thalassemia, produce variable severity.

Approximately 100,000 people in the United States live with sickle cell disease. More than 90% are Black or African American. Globally, roughly 300,000 babies are born with the condition each year, the overwhelming majority in sub-Saharan Africa and South Asia.

The sickle mutation persists at high frequency in populations where malaria is endemic because sickle cell trait confers partial resistance to Plasmodium falciparum. The same genetic variant that kills children who inherit two copies protects children who inherit one. This is textbook balanced selection, taught in every genetics course. It also means that sickle cell disease is concentrated among people of African, Mediterranean, Middle Eastern, and South Asian descent, a distribution that has shaped every political and medical decision about the condition for the past century.

Screening That Harmed

James Herrick published the first clinical description of sickle cell disease in 1910, after observing crescent-shaped red blood cells in a dental student named Walter Clement. By the 1970s, the biology was well understood. Screening tests existed. And a string of state legislatures decided to use them.

Between 1970 and 1972, twelve states passed laws mandating sickle cell screening for Black Americans. The laws targeted Black children at school entry and Black adults seeking marriage licenses. The programs screened for sickle cell trait, the carrier state, without clinical infrastructure to explain what trait status meant. Carriers are not sick. They do not have sickle cell disease. They carry one copy of the mutation and have a 25% chance of having an affected child if their partner is also a carrier.

The distinction between disease and trait was not communicated. Healthy Black Americans who tested positive for trait were denied health insurance. They were denied life insurance. They were denied jobs. The U.S. Air Force Academy barred applicants with sickle cell trait from admission. Stephen Pullens, a Black cadet, was forced to resign because of his carrier status. The Air Force did not rescind the policy until 1981.

Ted Veal of the People's Health Council of New York described the mandatory screening programs as "genocidal health practices" of the white medical establishment. The characterization was blunt. The evidence supported it. The programs offered no treatment, no genetic counseling, and no confidentiality protections. They produced stigma.

In 1972, Congress passed the National Sickle Cell Anemia Control Act, signed by President Nixon, which withheld federal funding from states that mandated testing. The law pushed screening toward voluntary programs with counseling. It did not undo the damage. A generation of Black families had learned that genetic testing could be used against them.

That history is the backdrop for every conversation about sickle cell screening, treatment access, and gene therapy pricing that follows.

Screening That Saved

Universal newborn screening for sickle cell disease began in the 1980s, driven by a single clinical trial.

The Prophylactic Penicillin Study (PROPS), published in 1986, demonstrated that oral penicillin given to infants with sickle cell anemia reduced the incidence of pneumococcal sepsis by 84%. Pneumococcal infection was the leading cause of death in young children with SCD. The trial was stopped early because the benefit was so clear that continuing to withhold penicillin from the control group was unethical.

The result changed the calculus. Screening now had an intervention attached to it. Identifying an affected infant at birth meant starting penicillin prophylaxis by two to three months of age, before the child's spleen lost function and left them vulnerable to encapsulated bacteria. The National Institutes of Health issued a consensus statement in 1987 recommending universal screening for all newborns, regardless of race or ethnicity.

By the early 2000s, all 50 states screened newborns for hemoglobinopathies. The test uses hemoglobin electrophoresis or high-performance liquid chromatography on the same dried blood spot collected for other newborn screening conditions. It identifies homozygous SS disease, hemoglobin SC disease, sickle beta-thalassemia, and carrier status in a single assay.

The shift from race-targeted mandatory screening in 1972 to race-neutral universal screening by 2000 is the corrective arc. The disease still disproportionately affects Black Americans, but the screening program no longer singles out Black families.

Standard of Care

A child identified with sickle cell disease through newborn screening in the United States today enters a care pathway that includes penicillin prophylaxis starting at two months of age and continuing through at least age five, hydroxyurea (the only disease-modifying oral therapy for decades, shown to reduce pain crises, acute chest syndrome, and mortality), routine vaccinations with additional coverage for encapsulated organisms, transcranial Doppler screening starting at age two to identify children at high risk for stroke, and chronic transfusion therapy for those with abnormal Doppler velocities.

This regimen has transformed outcomes. Median life expectancy for a person with sickle cell anemia in the United States has risen from the mid-teens in the 1970s to the mid-to-late 40s. The improvement is real and incomplete. Forty-five is not seventy-five. People with SCD still die decades earlier than the general population. They accumulate organ damage, chronic pain, and disability over a lifetime of vaso-occlusive crises. Every emergency department visit carries the risk that their pain will be undertreated because a provider assumes they are seeking drugs.

Hydroxyurea was approved for SCD in adults in 1998. The NIH recommended it for children nine months and older. It works by increasing production of fetal hemoglobin, which does not polymerize with hemoglobin S and prevents sickling. It reduces pain crises by roughly 50%. It is generic, inexpensive, and underused. Studies have consistently shown that Black children with SCD receive hydroxyurea at lower rates than the evidence supports, a gap attributed to provider hesitancy, family distrust of the medical system rooted in the history described above, and inadequate access to hematology subspecialty care.

The $2 Million Cure

On December 8, 2023, the FDA approved two gene therapies for sickle cell disease in people aged 12 and older with recurrent vaso-occlusive crises.

Casgevy (exagamglogene autotemcel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, is the first FDA-approved therapy using CRISPR/Cas9 gene editing. It edits the BCL11A gene in the person's own blood stem cells to reactivate fetal hemoglobin production. The edited cells are infused back into the person after myeloablative conditioning with busulfan chemotherapy. In clinical trials, 93.5% of treated individuals experienced no vaso-occlusive crises in the 12 months following infusion. The list price is $2.2 million.

Lyfgenia (lovotibeglogene autotemcel), developed by bluebird bio (now Genetix Bio), uses a lentiviral vector to add a modified beta-globin gene (producing HbAT87Q) to the person's stem cells. The modified hemoglobin functions like normal adult hemoglobin and does not polymerize. In trials, 88% of treated individuals were free of vaso-occlusive crises in the year after treatment. The list price is $3.1 million.

Both therapies require myeloablative conditioning, meaning the person undergoes chemotherapy to destroy their existing bone marrow before the corrected cells are infused. The process takes months. Fertility may be compromised. The conditioning itself carries significant risks. This is not an injection at a pharmacy. It is a bone marrow transplant with gene-corrected cells.

The results, for those who receive the therapies, are the closest thing to a cure that sickle cell disease has ever had.

Uptake

Two years after approval, the gene therapies are reaching fewer people than the clinical results would predict. By the end of 2025, 64 people with sickle cell disease or transfusion-dependent beta thalassemia had received infusions of Casgevy. Genetix Bio has treated over 100 people with Lyfgenia. These numbers are small against a U.S. population of 100,000 people with SCD.

The barriers are structural. The therapies require weeks to months at a specialized treatment center. Busulfan conditioning is toxic. The person must be healthy enough to survive the conditioning regimen, which excludes many adults with accumulated organ damage. Insurance coverage, while improving, often involves protracted prior authorization. Thirty-three states, the District of Columbia, and Puerto Rico now participate in the federal Cell and Gene Therapy Access Model, which ties Medicaid reimbursement to treatment outcomes. That model covers 84% of Medicaid beneficiaries with SCD. It does not cover the remaining 16%, and it does not address the commercial insurance market.

Vertex has announced plans to seek approval for Casgevy in children aged 5 to 11 in 2026. Earlier treatment, before organ damage accumulates, is likely to produce better outcomes. It also raises the question of whether a $2.2 million therapy will be accessible to Black children in states that have not joined the access model.

The Global Contrast

The math that makes gene therapy expensive in the United States makes it impossible everywhere else.

In Nigeria, roughly 150,000 babies are born with sickle cell disease each year, the highest burden of any country. A screening program at Aminu Kano Teaching Hospital screened 7,530 infants between 2020 and 2023, identifying 126 with SCD, a positivity rate of 1.7%. The American Society of Hematology's Consortium on Newborn Screening in Africa has established ten centers across seven countries, testing approximately 74,000 samples through mid-2024. These programs are pilot projects. They do not cover the population.

India launched a national sickle cell mission in 2023. By early 2025, the program had screened over 33 million people, identified 975,000 trait carriers, and diagnosed 140,000 with SCD. The scale is extraordinary: roughly 400 new cases identified daily. India's program is a carrier screening and diagnosis initiative, not a newborn screening panel equivalent. Treatment infrastructure varies by state.

In sub-Saharan Africa, where the majority of the world's sickle cell disease burden falls, childhood mortality for unscreened, untreated children with SCD ranges from 50% to 90% before age five, depending on access to basic healthcare. The contrast between a child born with SCD in Houston and a child born with the same disease in Lagos is the most extreme health equity gap on the newborn screening panel. The child in Houston is screened at two days of age, started on penicillin by two months, offered hydroxyurea by nine months, and potentially eligible for a $2.2 million gene therapy by age five. The child in Lagos may never be diagnosed. If diagnosed, penicillin prophylaxis may not be consistently available. Hydroxyurea access is limited. Gene therapy is out of the question.

What the Data Shows

Sickle cell disease is the condition that exposes every structural fault in rare disease infrastructure. It is common enough to generate large datasets but underfunded relative to conditions that affect predominantly white populations. Cystic fibrosis, which affects roughly 40,000 people in the United States (compared to 100,000 with SCD), received its first disease-modifying therapy (ivacaftor) in 2012 and its transformative combination therapy (Trikafta) in 2019. The CF Foundation's venture philanthropy model generated over $3 billion in royalties from Trikafta alone. No comparable funding structure exists for sickle cell disease.

The NIH funding disparity has been documented repeatedly. A 2020 analysis in JAMA Network Open found that NIH funding per person affected was roughly $800 per year for cystic fibrosis and $200 per year for sickle cell disease. The gap has narrowed in recent years but has not closed.

The gene therapy approvals in December 2023 represented the end of one kind of waiting and the beginning of another. The science arrived. The question is whether the infrastructure, the funding, and the political will to deliver it will follow, or whether sickle cell disease will remain the condition where the distance between what medicine can do and what medicine does do is measured in the skin color of the person who needs it.